Investigational Drug Information for KHK7791
✉ Email this page to a colleague
What is the development status for investigational drug KHK7791?
KHK7791 is an investigational drug.
There have been 7 clinical trials for KHK7791.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 8th 2021.
The most common disease conditions in clinical trials are Hyperphosphatemia and [disabled in preview]. The leading clinical trial sponsors are Kyowa Kirin Co., Ltd., Kyowa Hakko Kirin Co., Ltd, and [disabled in preview].
There are thirteen US patents protecting this investigational drug and one hundred and twenty-seven international patents.
Summary for KHK7791
| US Patents | 13 |
| International Patents | 127 |
| US Patent Applications | 49 |
| WIPO Patent Applications | 38 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 3 (2021-03-08) |
| Vendors | 40 |
Recent Clinical Trials for KHK7791
| Title | Sponsor | Phase |
|---|---|---|
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis | Kyowa Kirin Co., Ltd. | Phase 3 |
| Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis | Kyowa Kirin Co., Ltd. | Phase 3 |
| Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis | Kyowa Kirin Co., Ltd. | Phase 3 |
Clinical Trial Summary for KHK7791
Top disease conditions for KHK7791
Top clinical trial sponsors for KHK7791
US Patents for KHK7791
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| KHK7791 | ⤷ Sign Up | sGC stimulators | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| KHK7791 | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| KHK7791 | ⤷ Sign Up | NHE3-binding compounds and methods for inhibiting phosphate transport | ARDELYX, INC. | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
